What question did this study set out to answer?

To develop a highly effective, low-toxicity cobalt(II) liposomal agent that selectively inhibits tumor growth by targeting mitochondria and activating immune responses.

June 11, 2025Journal of Medicinal Chemistry

Development of a High-Efficacy and Low-Toxicity Cobalt(II) Agent for Targeting Inhibition of Tumor Growth through Mitochondrial Damage-Mediated Chemotherapy and Immunotherapy

View Full Paper

Ask AI

Bookmark

Authors

MZMinghui Zhu SXShihang Xu GLGuochao Li

Discussion

Member takes

Overview

Preclinical study demonstrates targeted tumor inhibition by liposomal cobalt(II) complexes in animal models, suggesting a safer alternative to platinum chemotherapy.

Key Points

To develop a highly effective, low-toxicity cobalt(II) liposomal agent that selectively inhibits tumor growth by targeting mitochondria and activating immune responses.
Synthesized and screened a series of cobalt(II) α-N-heterocyclic thiosemicarbazone complexes to identify a lead candidate (C3) showing potent in vitro cytotoxicity against tumor cells.
Formulated a liposome-encapsulated delivery system (C3-Lip) and evaluated its antitumor efficacy, biodistribution, toxicity, and mechanism of action in tumor-bearing models.
C3 and C3-Lip significantly suppressed tumor growth in vivo with virtually no observable toxic side effects, while C3-Lip demonstrated superior targeting and therapeutic efficiency relative to unencapsulated C3.
Mechanistic assays revealed that the agents bypass tumor cell DNA, instead disrupting mitochondrial respiratory function to deplete energy metabolism and triggering immunogenic cell death.

Cite This Study

Zhu et al. (2025) studied this question.

synapsesocial.com/papers/6a7d678d2d005ba2c41cd58b https://doi.org/10.1021/acs.jmedchem.5c01235

View Full Paper

Ask AI

Bookmark

June 11, 2025Journal of Medicinal Chemistry

Development of a High-Efficacy and Low-Toxicity Cobalt(II) Agent for Targeting Inhibition of Tumor Growth through Mitochondrial Damage-Mediated Chemotherapy and Immunotherapy

View Full Paper

Ask AI

Bookmark

Authors

MZMinghui Zhu SXShihang Xu GLGuochao Li

Discussion

Member takes

Overview

Preclinical study demonstrates targeted tumor inhibition by liposomal cobalt(II) complexes in animal models, suggesting a safer alternative to platinum chemotherapy.

Key Points

To develop a highly effective, low-toxicity cobalt(II) liposomal agent that selectively inhibits tumor growth by targeting mitochondria and activating immune responses.
Synthesized and screened a series of cobalt(II) α-N-heterocyclic thiosemicarbazone complexes to identify a lead candidate (C3) showing potent in vitro cytotoxicity against tumor cells.
Formulated a liposome-encapsulated delivery system (C3-Lip) and evaluated its antitumor efficacy, biodistribution, toxicity, and mechanism of action in tumor-bearing models.
C3 and C3-Lip significantly suppressed tumor growth in vivo with virtually no observable toxic side effects, while C3-Lip demonstrated superior targeting and therapeutic efficiency relative to unencapsulated C3.
Mechanistic assays revealed that the agents bypass tumor cell DNA, instead disrupting mitochondrial respiratory function to deplete energy metabolism and triggering immunogenic cell death.

Cite This Study

Zhu et al. (2025) studied this question.

synapsesocial.com/papers/6a7d678d2d005ba2c41cd58b https://doi.org/10.1021/acs.jmedchem.5c01235

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark